多粘菌素B在重症患者中的群体药物代谢动力学研究进展

中国药物评价 ›› 2024, Vol. 41 ›› Issue (6): 446-451.

多粘菌素B在重症患者中的群体药物代谢动力学研究进展

程贤雄1，莫银竹1，吕仕杰1，李志伟1，2，任宝军1，2，郑鹏肖1，2，梁爱君1，2，杨焕芝1，2*

1.昆明医科大学附属甘美医院，云南昆明 650000；
2.昆明市第一人民医院，云南昆明 650000

收稿日期:2024-08-16 修回日期:2024-11-21 出版日期:2024-12-28 发布日期:2024-12-28
基金资助:
昆明市卫生健康委员会卫生科研课题项目(No.2022-11-01-012；No.2023-21-01-002)；云南省科技厅重大科技专项计划项目(No.202302AA310018-F-7)；云南省教育厅科学研究基金项目(No.2024J0376)；昆明医科大学研究生创新基金项目（No.2024S386）：昆明市卫生科技人才培养项目[No. 2024-SW（领军）-10]

Advances in Population Pharmacokinetic Studies of Polymyxin B in Critically Ill Patients

1.Affiliated GanMei Hospital of Kunming Medical University， Yunnan Kunming 650000， China；
2.Departmentof Pharmacy， The First people′s Hospital of Kunming， Yunnan Kunming 650000， China

Received:2024-08-16 Revised:2024-11-21 Online:2024-12-28 Published:2024-12-28

摘要/Abstract

摘要： 在重症监护室中多重耐药菌具有复杂性、难治性的特点，会导致患者住院时间延长，病死率增加，多粘菌素B作为多重耐药性革兰氏阴性菌的最后选择之一。由于重症感染患者表现出个体间和个体内药代动力学的显著差异给抗感染治疗带来了巨大挑战。本文就多粘菌素B的药理作用、在重症患者中的药动学、药效学以及群体药物代谢动力学研究进展进行概述，以期为临床合理用药提供思路。

关键词: font-size:medium, ">多粘菌素B；重症患者；药动学；药效学；群体药物代谢动力学

Abstract: Multidrug-resistant bacteria in the intensive care unit are complex and refractory， leading to prolonged hospitalisation and increased morbidity and mortality， and polymyxin B serves as one of the last options for multidrug-resistant Gram-negative bacteria. The significant inter-and intra-individual pharmacokinetic differences exhibited by patients with severe infections pose a great challenge to anti-infective therapy. This article provides an overview of the pharmacological effects of polymyxin B， pharmacokinetics， pharmacodynamics， and progress in population pharmacokinetic studies in critically ill patients， with a view to providing ideas for rational clinical use of the drug.

Key words: font-size:medium, ">Polymyxin B；Critically ill patient；Pharmacokinetics；Pharmacodynamics；Population pharmacokinetics

中图分类号:

程贤雄1, 莫银竹1, 吕仕杰1, 李志伟1, 2, 任宝军1, 2, 郑鹏肖1, 2, 梁爱君1, 2, 杨焕芝1, 2. 多粘菌素B在重症患者中的群体药物代谢动力学研究进展[J]. 中国药物评价, 2024, 41(6): 446-451.

CHENG Xian-xiong1, MO Yin-zhu1, LV Shi-jie1, LI Zhi-wei1, 2, REN Bao-jun1, 2, ZHENG Peng-xiao1, 2, LIANG Ai-jun1, 2, YANG Huan-zhi1, 2. Advances in Population Pharmacokinetic Studies of Polymyxin B in Critically Ill Patients[J]. CHINESE JOURNAL OF DRUG EVALUATION, 2024, 41(6): 446-451.

参考文献

[1] Ryan KJ， Schainuck LI， Hickman RO， et al. Colistimethate toxicity. Report of a fatal case in a previously healthy child[J]. JAMAJ AM Med Assoc， 1969，207(11)：2099-2101.
     [2] Koch-Weser J， Sidel VW， Federman EB， et al. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy[J]. Ann Intern Med， 1970，72(6)：857-868.
     [3] Li J， Nation RL， Turnidge JD， et al. Colistin： the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections[J].Lancet Infect Dis，2006，6：589-601.
     [4] Zavascki AP， Goldani LZ， Li J， et al. Polymyxin B for the treatment of multidrug-resistant pathogens： a critical review[J]. J Antimicrob Chemoth，2007， 60： 1206-1215.
     [5] Landman D， Georgescu C， Martin DA， et al. Polymyxins revisited[J]. Clin Microbiol Rev，2008， 21： 449-465.
     [6] Falagas ME， Kasiakou SK. Colistin： the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections[J]. Clin Infect Dis，2005，40：1333-1341.
     [7] Lin QY， Tsai YL， Liu MC， et al. Serratia marcescens arn， a PhoP-regulated locus necessary for polymyxin B resistance[J]. Antimicrob Agents Ch，2014，58：5181-5190.
     [8] Imlay JA. The molecular mechanisms and physiological consequences of oxidative stress： lessons from a model bacterium[J]. Nat Rev Microbiol，2013， 11： 443-454.
     [9] Kohanski MA， Dwyer DJ， Hayete B， et al. A common mechanism of cellular death induced by bactericidal antibiotics[J]. Cell.2007， 130：797-810.
     [10] Dwyer DJ， Kohanski MA， Hayete B， et al. Gyrase inhibitors induce an oxidative damage cellular death pathway in Escherichia coli[J]. Mol Syst Biol，2007，3：91.
     [11] Abdul-Aziz MH， Alffenaar JC， Bassetti M， et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients： a Position Paper[J]. IntensS Care Med，2020，46：1127-1153.
     [12] Craig WA. Pharmacokinetic/pharmacodynamic parameters： rationale for antibacterial dosing of mice and men.[J]. Clin Infect Dis，1998，26：1-10， 11-12.
     [13] Mouton JW， Dudley MN， Cars O， et al. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs： an update[J].J Antimicrob Chemoth，2005，55：601-607.
     [14] Weiner-Lastinger LM， Abner S， Edwards JR， et al. Antimicrobial-resistant pathogens associated with adult healthcare-associated infections： Summary of data reported to the National Healthcare Safety Network， 2015-2017[J].Infect Cont Hosp Ep，2020，41：1-18.
     [15] Tsuji BT， Pogue JM， Zavascki AP， et al. International Consensus Guidelines for the Optimal Use of the Polymyxins： Endorsed by the American College of Clinical Pharmacy (ACCP)， European Society of Clinical Microbiology and Infectious Diseases (ESCMID)， Infectious Diseases Society of America (IDSA)， International Society for Anti-infective Pharmacology (ISAP)， Society of Critical Care Medicine (SCCM)， and Society of Infectious Diseases Pharmacists (SIDP) [J].Pharmacotherapy，2019，39：10-39.
     [16] Wang P， Liu S， Sun T， et al. Daily fluid intake as a novel covariate affecting the population pharmacokinetics of polymyxin B in patients with sepsis[J]. Int J Antimicrob AG， 2024，63(3)：107099.
     [17] Liang D， Liang Z， Deng G， et al. Population pharmacokinetic analysis and dosing optimization of polymyxin B in critically ill patients[J]. Front Pharmacol， 2023，14(null)：1122310.
     [18] Pi MY， Cai CJ， Zuo LY， et al. Population pharmacokinetics and limited sampling strategies of polymyxin B in critically ill patients[J]. J Antimicrob Chemoth， 2023，78(3)：792-801.
     [19] Wang P， Xing H， Zhang F， et al. Population pharmacokinetics of polymyxin B in critically ill patients receiving continuous venovenous haemofiltration[J]. Int J Antimicrob Ag， 2022，60(1)：106599.
     [20] Ye Q， Wang Q， Chen W， et al. The population pharmacokinetics and dose optimization of polymyxin B in critically ill patients with or without extracorporeal membrane oxygenation[J]. J Clin Pharmther， 2022，47(10)：1608-1618.
     [21] Luo X， Zhang Y， Liang P， et al. Population pharmacokinetics of polymyxin B and dosage strategy in critically ill patients with/without continuous renal replacement therapy[J]. Eur J Pharm SCI， 2022，175(null)：106214.
     [22] Yu XB， Jiao Z， Zhang CH， et al. Population pharmacokinetic and optimization of polymyxin B dosing in adult patients with various renal functions[J].Brib J Clin Pharmaco. 2021，87： 1869-1877.
     [23] Wang P， Zhang Q， Zhu Z， et al. Comparing the Population Pharmacokinetics of and Acute Kidney Injury Due to Polymyxin B in Chinese Patients with or without Renal Insufficiency[J].Antimicrob Agents CH， 2021：65.
     [24] Sandri AM， Landersdorfer CB， Jacob J， et al. Population pharmacokinetics of intravenous polymyxin B in critically ill patients： implications for selection of dosage regimens[J].Clin Infect Dis. 2013，57：524-531.
     [25] Surovoy YA， Burkin MA， Galvidis IA， et al. Comparative polymyxin B pharmacokinetics in patients receiving extracorporeal membrane oxygenation[J].J Antimicrob Chemoth， 2022，77： 1379-1384.
     [26] Poursoleiman A， Karimi-Jafari MH， Zolmajd-Haghighi Z， et al. Polymyxins interaction to the human serum albumin： A thermodynamic and computational study[J]. Spectrochim Acta A， 2019，217(null)：155-163.
     [27] Chen N， Guo J， Xie J， et al. Population pharmacokinetics of polymyxin B： a systematic review[J]. Ann Transl Med，2022，10： 231.